News Roundup: Himax Technologies, Inc. (ADR) (NASDAQ:HIMX); Arch Coal Inc (NYSE:ACI) And Walgreen Company (NYSE:WAG)

Boston, MA, 02/19/2014 – Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) posted its fourth quarterly results last week which met expectations of the street both in terms of revenue and EPS. While its EPS came in line at $0.10 per share, its revenue exceeded the consensus by $1.89 million to $195.2 million, which is 2.4% increase year-over-year. Himax projected better revenue for the current quarter accounting a growth of 11.1% as against the previous year, but faltered on the EPS estimate of $0.083-$0.098, below $0.10 expectation. The chipmaker indicated that the price competition prevalent in low-end smartphone and CMOS image sensor inventory correction will impact margins in the near term, but the same is expected to reach stability towards the end in 2014.

One of the key takeaway from Arch Coal Inc (NYSE:ACI)‘s posted quarterly report is its vision that the demand for metalurgical coal is bound to improve in the near future. The fact could be deduced from Arch’s move to add Leer mine in its assets to boost the production of metallurgical coal. Arch, clearly wants to capture the coking coal market and it is evident from its move to add Leer mine, which will produce 70% of output as coking coal Leer mine could be counted as the biggest advantage for Arch due to its good quality coal and strategic access to the seaborne market. Even half of the output at Leer’s mine has already found a market. Therefore, going forward, Arch Coal Inc (NYSE:ACI)’s metallurgical output will be contributed by low cost Leer and Mountain Laurel mines, mirroring the optimistic demand growth perceived by the Arch’s management.

Walgreen Company (NYSE:WAG) announced this week that it is extending its Connected Care hepatitis C program to over 100 pharmacies specialized in hepatitis C. The Connected Care is a program designed to aid patients attain a sustained virologic response (SVR) and improve their quality of life through medication. The decision comes at a time when the treatment therapies are rapidly advancing.

Like it? Share it!

Leave A Response